"23andMe's fall from a $6B valuation to penny stock status is a cautionary tale of high-risk speculation in the crypto and finance world. CEO Anne Wojcicki's price hikes may not be enough to revive the struggling genetics company. Investors should proceed with caution, as 23andMe's downfall highlights the perils of speculative bets."